PentaBind, an AI-led aptamer design and therapeutics company is generating the next generation of oligonucleotide-based targeted therapeutics for oncology with its integrated ‘damp-lab’ platform. Aptamers are short single stranded DNA/RNA-based ligands that bind to disease-associated antigens with high affinity (nanomolar-picomolar range)1. Unlike antibodies, aptamers are smaller, synthetically manufactured and easy to modify without compromising function – making them ideal carriers for diverse payloads such as radioligands and cytotoxic drugs.